Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769663 | 1.00 | NFE2L2 (0.41) | NFE2L2HPGDTRPA1NPC1RAB9A | |
| SCHEMBL3764145 | 0.90 | NPC1 (0.39) | HPGDTRPA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3662523 | 0.90 | NPC1 (0.39) | HPGDTRPA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3782296 | 0.88 | NFE2L2 (0.47) | NFE2L2TRPA1MAPT | |
| SCHEMBL3782287 | 0.88 | NFE2L2 (0.47) | NFE2L2TRPA1MAPT | |
| SCHEMBL3768892 | 0.85 | NFE2L2 (0.47) | NFE2L2TRPA1NPC1 | |
| SCHEMBL3768896 | 0.85 | NFE2L2 (0.47) | NFE2L2TRPA1NPC1 | |
| SCHEMBL3662395 | 0.83 | NFE2L2 (0.38) | NFE2L2HPGDTRPA1NPC1RAB9A | |
| SCHEMBL3776287 | 0.83 | NFE2L2 (0.38) | NFE2L2HPGDTRPA1NPC1RAB9A | |
| SCHEMBL3772509 | 0.81 | NFE2L2 (0.46) | NFE2L2NPC1SMN1; SMN2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | disclosed |
| EP-2234488-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077443-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, NOX5, TET1 | NFE2L2 825/4885HPGD 174/4885TRPA1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.